Philippine Journal of Science
152 (6A): 2129-2137, December 2023
ISSN 0031 – 7683
Date Received: 23 May 2023

Drug-Excipient Compatibility Testing of Cilostazol
Using FTIR and DSC Analysis

Syrine Faith Diño1, Alia Denise Edu1, Ralph Gean Francisco1,
Emmanuel Gutierrez1, Perlita Crucis1,2*, April Mergelle Lapuz1,
Rogie Royce Carandang1,3, and Kevin Jace Miranda1

1College of Pharmacy, Adamson University,
Ermita, Manila, Metro Manila 1000 Philippines
2Graduate School, Centro Escolar University,
San Miguel, Manila, Metro Manila 1008 Philippines
3Department of Public Health Sciences,
University of Connecticut School of Medicine, Farmington, CT 06030 USA

*Corresponding author: pcrucis@adamson.edu.ph

[Download]
Diño SF et al. 2023 Drug-Excipient Compatibility Testing of Cilostazol
Using FTIR and DSC Analysis. Philipp J Sci 152(6A): 2129–2137.
https://doi.org/10.56899/152.6A.08

 

ABSTRACT

Cilostazol possesses pharmacological restrictions, such as its absorption being limited by its dissolution rate, and formulation studies must be employed accordingly to generate an optimized formulation. A drug-excipient compatibility analysis is conducted to determine any interactions that may affect the formulation in order to guarantee the stability, bioavailability, and manufacturability of solid dosage forms. To identify any incompatibilities, cilostazol alone and in combination with the individual excipients such as microcrystalline cellulose, crospovidone, magnesium stearate, isopropyl alcohol, sodium lauryl sulfate, polyvinylpyrrolidone K30, and corn starch were subjected to Fourier-transform infrared spectroscopy (FTIR) equipped with an attenuated total reflectance method and heat-flow differential scanning calorimetry (DSC) with a temperature ranging from 30–400 °C at 10 °C/min ramp rate. The FTIR analysis of cilostazol alone and combined with excipients revealed no evidence of chemical or physical instability. Minor changes in the appearance of the absorbance bands in the FTIR comparison can be seen primarily due to the chemical characterization of the excipients, but the characteristic peaks of cilostazol were still present. As for DSC compatibility analysis, the % difference in cilostazol’s principal peak temperature alone and with excipients showed no significant change. This implies that no incompatibilities exist between cilostazol and the excipients.